- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02629250
Supernormal Oxygen Delivery for Elderly Surgical Patients (SNODES)
February 14, 2017 updated by: Xiangcai Ruan, MD, PhD, Vice-Director in Dept Anesth & Pain, Guangzhou First People's Hospital
A Randomized Controlled Study of Supernormal Oxygen Delivery Goal-directed Therapy for Elderly Patients Undergoing Proximal Femoral Surgery.
Elderly patients with poor cardiopulmonary reserve tend to suffer higher risk and develop more complications following major surgery.
Quite a few researches have shown the benefits of goal-directed therapy (GDT) using fluid loading or inotropic agents or both to improve outcome during major surgery.
However there is concern that inotropic therapy for a supernormal oxygen delivery (DO2I) may lead to an increased incidence of myocardial ischemia.
Even though the meta-analysis has stated that DO2I strategy could possibly reduce the incidence of cardiac complication than stroke volume optimization strategy, there are very few evidence available in the literature regarding the effect on myocardial ischemia in surgical patients, especially in non-cardiac surgical patients.
This study is undertaken to test the hypothesis that an intraoperative DO2I optimization result in a decreased myocardial ischemia in the elderly high-risk surgical patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Elderly patients with poor cardiopulmonary reserve tend to suffer higher risk and develop more complications following major surgery [1].
Quite a few researches have shown the benefits of goal-directed therapy(GDT) using fluid loading or inotropic agents or both to improve outcome during major surgery [2-7].
The maintenance of adequate tissue perfusion and global oxygen delivery (DO2I) is essential to maintain adequate tissue perfusion and oxygenation in relation to increased metabolic demand during high risk surgery.
However, there is concern that inotropic therapy for a supernormal oxygen delivery may lead to an increased incidence of myocardial ischemia [8].
Even though the meta-analysis has stated that DO2I optimization could possibly reduce the incidence of cardiac complication than stroke volume optimization strategy [9],there are very few evidence available in the literature regarding the effect on myocardial ischemia in surgical patients, especially in non-cardiac surgical patients.
This study is undertaken to test the hypothesis that an intraoperative DO2I optimization result in a decreased myocardial ischemia in the elderly high-risk surgical patients.
The investigators will conduct a prospective, randomized, controlled, double-blinded trial in seventy patients who scheduled for proximal femur surgery under General anesthesia following nerve block.
Both the patients will be allocated to one of two equal groups to receive either intraoperative fluid regimen guided by SV strategy or DO2I strategy.
In the control(SV) group, the patients will receive an intravenous infusion of 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume maximization.
In the experimental(DO2I) group, fluid and dobutamine will be given to reach a stroke volume maximization and supernormal oxygen delivery.
The primary outcome is preoperative and 24h postoperative serum concentration of troponin T. Secondary outcomes include the incidence of tachycardia, arrhythmia, myocardial infarction, pneumonedema and acute heart failure, blood pressure, pulmonary infection, fluid volume, blood transfusion volume, renal function, PONV, Length of postoperative hospital stay and mortality.
Data will be collected and recorded by the clinical teams who are blind to study arm allocation.
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiangcai Ruan, MD, PhD
- Phone Number: +8620-81048306
- Email: xc_ruan@hotmail.com
Study Contact Backup
- Name: Jingjing Tang
- Phone Number: +8618898533061
- Email: 15059038216@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510180
- Recruiting
- Guangzhou First People's Hospital
-
Principal Investigator:
- Xiangcai Ruan, MD, PHD
-
Contact:
- Xiangcai Ruan, MD, PHD
- Phone Number: 86-20-81048306
- Email: xc_ruan@hotmail.com
-
Sub-Investigator:
- Bin Zheng, MD, Msc
-
Sub-Investigator:
- Jingjing Tang, MD
-
Sub-Investigator:
- Chengxiang Lu, MD, Msc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
70 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients scheduled for proximal femur fracture (PFF) surgery at this institution
- American Society of Anaesthesiologists (ASA) physical status of III or VI
- Two or more risk factors according to risk index of Lee
Exclusion Criteria:
- Patient age < 70 yrs
- Ongoing myocardial infarct or ischemia
- Chronic haemodialysis
- Inability to cooperate in the study
- Patient refusal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: SV maximization
Goal-directed fluid therapy with stroke volume maximization.
Device: The Volume-View system from Edwards Co.
|
When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR <100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization.
The fluid challenge will repeat until the SV failed to increase by a factor of 10%.
A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml.
Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
Other Names:
|
Experimental: supernormal DO2
Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery. Device: The Volume-View system from Edwards Co. |
Goal directed fluid therapy is administrated as group SV maximization.
Then DO2I will be assessed.
If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given.
Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in concentration of troponin T at 24 hours postoperatively
Time Frame: preoperative value and 24 hours postoperatively
|
Intraoperative supernormal oxygen delivery strategy will reduce the changes in concentration of troponin T at 24 hours postoperatively.
|
preoperative value and 24 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiac complication up to 24 hours postoperatively
Time Frame: up to 24 hours postoperatively
|
Occurrence of newly diagnosed arterial fibrilation ,severe arrhythmia,clinical signs of unstable angina, myocardial infarction,pulmonary edema or therapy-requiring cardiac failure.
|
up to 24 hours postoperatively
|
blood pressure
Time Frame: up to 24 hours postoperatively
|
Invasive arterial BP(mmHg) is measured through an arterial line at the arm.episode of hypotension (30% decrease in mean BP in relation to baseline values) and hypertension (30% increase in mean BP in relation to baseline values) will be recorded.
|
up to 24 hours postoperatively
|
heart rate (HR)
Time Frame: up to 24 hours postoperatively
|
HR(beats/min), bradycardia (HR < 50 beats/min), and tachycardia (HR > 100 beats/min) will be recorded at the same time as BP recording.
|
up to 24 hours postoperatively
|
SpO2
Time Frame: up to 24 hours postoperatively
|
SpO2(%) and hypoxemia (SpO2 <90%) will be recorded at the same time as BP recording.
|
up to 24 hours postoperatively
|
fluid balance
Time Frame: up to 24hours after surgery
|
amount of fluids (ml) infused, amount of fluid losses
|
up to 24hours after surgery
|
blood transfusion volume
Time Frame: up to 24 hours postoperatively
|
amount of blood transfusion, amount of blood losses.
|
up to 24 hours postoperatively
|
Acute Kidney Injury
Time Frame: up to 24 hours postoperatively
|
perioperative and 24h postoperative urine volume, serum creatinine, blood urea nitrogen.
|
up to 24 hours postoperatively
|
Postoperative Nausea and Vomiting (PONV)
Time Frame: 24 hours postoperatively
|
Postoperative Nausea and Vomiting, The incidence of PONV will be recorded using a 4-point objective score (1 = no PONV;2 = mild nausea, no vomiting; 3 = excessive nausea or vomiting;4 = vomiting ≥2 times).
|
24 hours postoperatively
|
length of postoperative hospital stay
Time Frame: 28 days postoperatively
|
days from end of surgery to hospital discharge
|
28 days postoperatively
|
mortality
Time Frame: 28 days postoperatively
|
mortality within 28 days after surgery
|
28 days postoperatively
|
cardiac complication at 28 days postoperatively
Time Frame: 28 days postoperatively
|
Occurrence of newly diagnosed arterial fibrilation ,severe arrhythmia,clinical signs of unstable angina, myocardial infarction,pulmonary edema or therapy-requiring cardiac failure.
|
28 days postoperatively
|
incidence of pulmonary infection
Time Frame: up to 28 days postoperatively
|
number of patients having pulmonary infection requiring intravenous antibiotic therapy
|
up to 28 days postoperatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative pain
Time Frame: 24 hours postoperatively
|
Postoperative pain using visual analog scale (VAS, 0-100, 0 = no pain, 100 = maximum imaginable pain) will be assessed.
|
24 hours postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiangcai Ruan, MD, PhD, Guangzhou First People's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Auler JO Jr, Michard F. Goal-directed fluid management based on pulse pressure variation monitoring during high-risk surgery: a pilot randomized controlled trial. Crit Care. 2007;11(5):R100. doi: 10.1186/cc6117.
- Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Crit Care. 2005;9(6):R687-93. doi: 10.1186/cc3887. Epub 2005 Nov 8.
- Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg. 2011 Jun;112(6):1392-402. doi: 10.1213/ANE.0b013e3181eeaae5. Epub 2010 Oct 21.
- Wilson J, Woods I, Fawcett J, Whall R, Dibb W, Morris C, McManus E. Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery. BMJ. 1999 Apr 24;318(7191):1099-103. doi: 10.1136/bmj.318.7191.1099.
- Donati A, Loggi S, Preiser JC, Orsetti G, Munch C, Gabbanelli V, Pelaia P, Pietropaoli P. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. Chest. 2007 Dec;132(6):1817-24. doi: 10.1378/chest.07-0621. Epub 2007 Oct 9.
- Fowkes FG, Lunn JN, Farrow SC, Robertson IB, Samuel P. Epidemiology in anaesthesia. III: Mortality risk in patients with coexisting physical disease. Br J Anaesth. 1982 Aug;54(8):819-25. doi: 10.1093/bja/54.8.819.
- Lobo SM, Lobo FR, Polachini CA, Patini DS, Yamamoto AE, de Oliveira NE, Serrano P, Sanches HS, Spegiorin MA, Queiroz MM, Christiano AC Jr, Savieiro EF, Alvarez PA, Teixeira SP, Cunrath GS. Prospective, randomized trial comparing fluids and dobutamine optimization of oxygen delivery in high-risk surgical patients [ISRCTN42445141]. Crit Care. 2006;10(3):R72. doi: 10.1186/cc4913. Epub 2006 May 12.
- Pearse RM, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett D. The incidence of myocardial injury following post-operative Goal Directed Therapy. BMC Cardiovasc Disord. 2007 Mar 19;7:10. doi: 10.1186/1471-2261-7-10.
- Futier E, Vallet B. Inotropes in goal-directed therapy: do we need 'goals'? Crit Care. 2010;14(5):1001. doi: 10.1186/cc9251. Epub 2010 Sep 29.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
February 1, 2017
Study Completion (Anticipated)
March 1, 2017
Study Registration Dates
First Submitted
December 9, 2015
First Submitted That Met QC Criteria
December 11, 2015
First Posted (Estimate)
December 14, 2015
Study Record Updates
Last Update Posted (Actual)
February 16, 2017
Last Update Submitted That Met QC Criteria
February 14, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GZZD-2015007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Femoral Fractures
-
RegeneCure, Ltd.UnknownProximal (Subtrochanteric)Femoral Fractures | Distal Femoral FracturesIsrael
-
Sundsvall HospitalCompletedFemoral Neck FractureSweden
-
Johns Hopkins UniversityRecruitingFemoral Fracture | Femoral Neck Fractures | Intertrochanteric FracturesUnited States
-
Sundsvall HospitalCompletedHip Fracture | Femoral Neck Fracture | Periprosthetic Femoral Fracture
-
Hospices Civils de LyonCompleted
-
RenJi HospitalRecruiting
-
Sorlandet Hospital HFCompleted
-
Hartford HospitalZimmer BiometCompletedFemoral Neck FractureUnited States
-
First Hospitals affiliated to the China PLA General...Unknown
-
Danderyd HospitalCompletedFemoral Neck FractureSweden
Clinical Trials on SV maximization
-
National Taiwan University HospitalUnknown
-
Rigshospitalet, DenmarkCompleted
-
Cosmo Technologies LtdCompletedInfectious Diarrhoea
-
Dartmouth-Hitchcock Medical CenterZimmer BiometCompletedKnee OsteoarthritisUnited States
-
ResMedMayo ClinicCompletedComplex Sleep Apnea SyndromeUnited States
-
AgNovos Healthcare, LLCRecruitingVertebral Fracture | Vertebral Compression Fracture | Vertebral CompressionGermany, Spain
-
Dr. Falk Pharma GmbHCompletedUncomplicated DiverticulitisGermany
-
Cosmo Technologies LtdCompletedDiarrhea-predominant Irritable Bowel SyndromeBelgium, Germany, Italy, Spain
-
RedHill Biopharma LimitedNot yet recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterRecruiting